Johnson & Johnson holds 2024 profit forecast steady after solid Q4 earnings
Johnson & Johnson says its on track to meet its 2025 target of $57 billion in pharmaceutical sales.…
16,220€
0,37%
Echtzeit-Aktienkurs Johnson Matthey PLC
Bid:
Ask:
Nachrichten zur Johnson Matthey PLC Aktie
Johnson & Johnson in charts: MedTech segment sales surged 13% Y/Y in Q4
…
Johnson & Johnson Q4 earnings beat estimates amid strength in medtech
…
Johnson & Johnson tops revenue estimates, reiterates forecast By Investing.com
Johnson & Johnson tops revenue estimates, reiterates forecast…
Johnson & Johnson narrowly tops quarterly estimates as pharmaceutical, medtech sales jump
The results come six months after J&J completed its spinoff of consumer health unit Kenvue, the companys biggest shake-up in…
Surgical Dressing Market Valuation to Reach US$1.9 Billion by 2030, Driven by 6.1% CAGR | Persistence Market Research
Discover the dynamic world of the surgical dressing market with a comprehensive market overview. Explore key statistics, technology trends, market…
Earnings week ahead: Tesla, Netflix, AT&T, Johnson & Johnson, GE and more
…
Wochenausblick - Die Quartalssaison steht in den Startlöchern.
WerbungZum Start in die neue Börsenwoche informieren wir jeden Sonntag über Wirtschaftsdaten, Quartalszahlen und mehr. Neben den Quartalszahlen von Netflix,…
Johnson & Johnson wins full FDA approval for bladder cancer therapy Balversa
…
Top 5 Life Science ETFs
Taking a position in a life science exchange-traded fund (ETF) provides exposure to a basket of stocks focused on the…
Johnson & Johnson likely to post dip in 4Q earnings
Johnson & Johnson (NYSE:JNJ) raised its full-year guidance after a strong third quarter which saw earnings beat expectations and its…
Johnson & Johnson: Is The Dividend Still Safe After The Kenvue Split-Off?
…
Johnson & Johnson: One Penny, Per Hour, Forever
…
S&P 500 zum Teil geschlagen: 15 Dividendenkönige, die seit 60 Jahren oder mehr ihre Ausschüttungen erhöhen
Diese 15 Aktienunternehmen, darunter Namen wie Procter & Gamble und Johnson & Johnson, haben ihre Dividenden seit mehr als 60…
The Zacks Analyst Blog Highlights Johnson & Johnson, Micron Technology, The Southern Company, TotalEnergies and PACCAR
Johnson & Johnson, Micron Technology, The Southern Company, TotalEnergies and PACCAR are part of the Zacks top Analyst Blog.…
Johnson & Johnson-Aktie mit leichten Kursgewinnen (147,4645 €)
Die Aktie von Johnson & Johnson notiert heute etwas fester. Zuletzt zahlten Investoren für das Papier 161,77 US-Dollar. Am Aktienmarkt…
Is Johnson & Johnson Stock a Buy Now? @themotleyfool #stocks $JNJ
The pharmaceutical giant recently announced another acquisition.…
Is Johnson & Johnson Stock a Buy Now?
The pharmaceutical giant recently announced another acquisition.…
Top Analyst Reports for Johnson & Johnson, Micron Technology & Southern Company
Todays Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Micron Technology, Inc. (MU)…
Johnson & Johnson: $2 Billion Buyout Of Antibody Drug Conjugate Specialist Ambrx Is Good Business
…
This Dividend Stock Has a $13 Billion Secret Weapon @themotleyfool #stocks $JNJ
Johnson & Johnson made a key decision last year.…
Johnson & Johnson (JNJ) J.P. Morgan 42nd Annual Healthcare Conference (Transcript)
…
Johnson & Johnson to acquire Ambrx Biopharma for $2 billion By Investing.com
Johnson & Johnson to acquire Ambrx Biopharma for $2 billion…
Johnson & Johnson: EPS Growth Returns In 2024, JPM Healthcare Conference On Tap
…
Johnson & Johnson erwirbt das Biotech Unternehmen Ambrx für 2 Milliarden Dollar
…
Johnson & Johnson: Übernahme lässt diese Aktie explodieren
Johnson & Johnson hat einen entscheidenden Schritt zur Erweiterung seines Onkologie-Portfolios unternommen, indem das Unternehmen die Absicht zur Akquisition eines…
Johnson & Johnson schlägt zu – 100 Prozent Aufschlag
Johnson & Johnson (J&J) wird 2,0 Milliarden Dollar in bar zahlen, um Ambrx Biopharma zu erwerben und damit einen Entwickler…
PRTG: Bridging I-O: Working in Harmony with Checkpoints
By John Vandermosten, CFA
NASDAQ:PRTG
READ THE FULL PRTG RESEARCH REPORT
We are initiating coverage of Portage Biotech Inc. (NASDAQ:PRTG) with a target…
Johnson & Johnson: 2,0 Milliarden Dollar für Ambrx Biopharma - Aktienanalyse
Kulmbach (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von "Der Aktionär":
Michael Diertl vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die…
Johnson & Johnson: Übernahme lässt diese Aktie explodieren
Johnson & Johnson plant die Übernahme eines Biotechnologieunternehmens für zwei Milliarden US-Dollar, um sein Onkologie-Portfolio zu erweitern.…
Johnson & Johnson to acquire Ambrx for $2B
Johnson & Johnson (NYSE:JNJ) has announced its definitive agreement to acquire Ambrx Biopharma, a clinical-stage biopharmaceutical company, in an all-cash...…
Johnson & Johnson to acquire Ambrx in $2 billion deal
…
Johnson & Johnson to Acquire Ambrx for $2 billion By Investing.com
Johnson & Johnson to Acquire Ambrx for $2 billion…